Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug entities : Eli lilly and company save search
Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
drug preclinical meeting
Global Irritable Bowel Disease (IBD) Market Research Report 2024: Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes Insights and Forecast 2019-2029
Published: 2024-03-13 (Crawled : 03:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.27%
H: 0.5%
C: 0.11%
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 0.59%
H: 0.01%
C: -1.45%
drug disease report research global market
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’sAgency to convene an advisory committee to consider the drug
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -2.29%
fda drug approval treatment
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
Published: 2024-03-08 (Crawled : 12:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -2.29%
drug food meeting study
Global Therapeutic Antibody Market Research Report 2024: Monoclonal, Bispecific, Drug Conjugates, Others Insights and Forecasts 2019-2029
Published: 2024-02-28 (Crawled : 03:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.36%
H: 0.1%
C: -0.6%
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 0.6%
H: 0.02%
C: -1.03%
drug report antibody research global market
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Published: 2024-02-07 (Crawled : 09:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.65%
H: 0.57%
C: -3.21%
first management drug application china
Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028, Assesses DelveInsight
Published: 2024-01-23 (Crawled : 23:00) - prnewswire.com
TRUMF | $16.81 -17.59% 1.5K
|
Health Technology
|
| O: -4.99%
H: 0.0%
C: -0.06%
TRUMY | $16.99 0.79% 50K
|
Manufacturing
|
| O: -1.36%
H: 0.0%
C: -0.82%
WST | $377.36 -0.56% 0.0% 360K
|
Health Technology
|
| O: 0.67%
H: 0.46%
C: -1.49%
TFX | $208.3 -0.86% 0.0% 170K
|
Health Technology
|
| O: 0.18%
H: 0.52%
C: -2.57%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.61%
H: 1.52%
C: 0.03%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.16%
H: 0.84%
C: 0.08%
BSX | $67.96 -0.24% 1.53% 6.2M
|
Health Technology
|
| O: -0.18%
H: 0.5%
C: -0.98%
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 1.44%
H: 0.0%
C: 0.0%
PODD | $166.245 -3.74% -3.89% 680K
|
Health Technology
|
| O: 0.07%
H: 1.08%
C: -1.59%
drug global growth market
Global Erectile Dysfunction Drugs Market Research Report 2024: Novel Drug Launches Propel Growth, Growing Geriatric Population Drives Demand - Forecast to 2034
Published: 2024-01-16 (Crawled : 00:00) - prnewswire.com
MGRX | $0.285 10.08% 9.16% 240K
|
|
| O: 3.28%
H: 4.38%
C: -0.19%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -2.03%
H: 0.05%
C: 0.05%
PTPI | $0.689 -2.27% -2.32% 460K
|
|
| O: 0.38%
H: 0.0%
C: -7.58%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.34%
H: 0.0%
C: 0.0%
drug propel report research global growing market
Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight
Published: 2024-01-15 (Crawled : 22:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
drug treatment heart market
Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline
Published: 2024-01-05 (Crawled : 14:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.08%
H: 0.97%
C: 0.74%
drug pipeline expansion immunology therapeutics
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
Published: 2023-12-13 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.95%
H: 3.83%
C: 2.79%
tyvyt drug china
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
Published: 2023-12-13 (Crawled : 05:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
HCM | $16.45 -1.38% -1.4% 290K
|
Health Technology
|
| O: -2.54%
H: 3.89%
C: 3.41%
elunate drug china
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
Published: 2023-12-04 (Crawled : 23:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
|
| O: 2.08%
H: 1.53%
C: 0.76%
drug food treatment pharmaceuticals application
PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
Published: 2023-11-28 (Crawled : 20:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
drug prism collaboration
Aspirin Drug Market to Soar to US$4.2 Billion by 2034, Driven by Combination Aspirin's Dominance | Future Market Insights, Inc.
Published: 2023-11-21 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
PRGO | $30.04 0.27% 0.0% 780K
|
Health Technology
|
| O: 0.66%
H: 1.87%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.44%
H: 0.63%
C: -0.05%
ABT | News | $105.9 -3.03% 0.07% 12M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
drug market
Global Cyclin-Dependent Kinase Inhibitor Drug Research Report 2023: Comprehensive Analysis of 45 Companies and 50+ Pipeline Drugs
Published: 2023-11-21 (Crawled : 18:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.44%
H: 0.63%
C: -0.05%
drug companies report pipeline research global
Redwire Announces First Spaceflight Mission for New Cutting-Edge Pharmaceutical Drug Development Lab, Partnering with Eli Lilly and Company to Expand Space Research to Study Heart Disease and Diabetes
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
drug disease company space research heart diabetes study
U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
Published: 2023-10-09 (Crawled : 18:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.21%
H: 2.8%
C: 1.37%
foundationone drug diagnostic food tumors companion
U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer
Published: 2023-10-02 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
drug food response
Addressing Unmet Needs: Uveitis Market Report Provides Opportunities for Drug Developers
Published: 2023-08-03 (Crawled : 18:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
drug report market
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.